Sharp seeks greater foothold in Chinese market through ClinsChain partnership

Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market

Sharp will partner with ClinsChain, who specialise in providing clinical supply services for local and global clinical trials, to facilitate access to the Chinese market for Sharp’s pharma and biopharma clients. The collaboration will also help Chinese companies to increase their global presence.  

Sharp says it will now be able to offer pharma clients local expertise for their clinical studies.  

Speaking about the news, Robert O’Beirn, Managing Director at Sharp Clinical commented: ‘We are delighted to announce our partnership with ClinsChain, demonstrating our commitment to supporting our clients in the burgeoning Chinese market.  

‘This partnership represents an alliance of two trusted and experienced clinical service providers which will ensure our clients benefit from the best of local knowledge and global reach for their clinical trials.’  

ClinsChain founder Paul Cao added that the company has ‘invested significant time looking for a strong global partner’ and had been ‘very impressed with Sharp’s experience and broad expertise in the clinical trial packaging market.’ 

He continued: ‘Expanding ClinsChain’s reach to new markets and helping Chinese innovators reach new global markets is a vital part of our growth strategy for the future. This partnership with Sharp is an important contribution to delivering that strategy.’  

Sharp also recently expanded its clinical service offering in Europe through the addition of labelling and secondary packaging services at its Heerenveen facility in the Netherlands.